Featured News

An omicron COVID virus. A gray virus with red and orange projections.
The effect of Omicron BA.1-based booster mRNA vaccination on the incidence of COVID-19
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
This is an HIV antibody with a yellow core and pink outer shell.
Targeting HIV broadly neutralizing antibody precursors with precision in humans.
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
Picture of antibodies.
HIV vaccine using mRNA-encoded nanoparticles showed to be safe and well-tolerated
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
Flyer of Featured Presentation by Dr. Nadine Rouphael, Executive Director of the Hope Clinic at the Emory Vaccine Center
NEW Seminar Series: State-of-the-art Topics in Vaccinology
You are invited to attend the first featured presentation in the "State-of-the-Art Topics in Vaccinology" Seminar Series on Tuesday January 28, 2025 at 2 pm. by Dr. Nadine Rouphael, Executive Director of the Hope Clinic at the Emory Vaccine Center.
A needle withdraws the vaccine in an RSV vial.
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV
mpox virus particles from NIAID Integrated Research Facility (credit: NIAID)
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
The mpox virus under a microscope
The Mpox Vaccine, MVA-BN, Receives Approval for Use in Adolescents 12 - 17 years of age
The GW VRU contributed critical data needed to approve the use of the Mpox vaccine in adolescents. This is of huge importance given the current Mpox outbreak has yet to be controlled and has disproportionately impacted children in this wave.
Pfizer's RSV vaccine, Abrysvo, has shown a strong immune response and well-tolerated safety profile in new study.
Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.
Young child smiling with his armed raised. There is a band-aid are the arm to indicate that he has received a vaccination.
Check out the CDC's new report titled 'Health and Economic Benefits of Routine Childhood Immunizations in the Era of the Vaccines for Children Program - United States, 1994 - 2023
The CDC has released a new report on the health and economic benefits of routine childhood immunizations since the creation of the Vaccines for Children (VFC) program in 1994.
Individuals of all ages smiling. Vaccines help protect you throughout your life. Talk to a healthcare provider you trust about staying up to date on recommended vaccines.
August is National Immunization Awareness Month
It's National Immunization Awareness Month! Getting vaccinated on the recommended schedule is an important part of protecting against many diseases. Please check with your trusted provider to see what vaccines are recommended for you!
Subscribe to Featured News